The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
The resurgence of platinum-based cancer chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cited by
Items 101–144 of 144
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 287
Metal-containing and related polymers for biomedical applications
Yan, Y., Zhang, J., Ren, L., & Tang, C. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00026f · Cited by 283
Arnesano, F., & Natile, G. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.01.028 · Cited by 282
Redox‐Active Metal Complexes for Anticancer Therapy
Zhang, P., & Sadler, P. J. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600908 · Cited by 274
Freyer, D. R., Chen, L., Krailo, M. D., Knight, K., Villaluna, D., Bliss, B., Pollock, B. H., Ramdas, J., Lange, B., Van Hoff, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30625-8 · Cited by 267
A selective USP1–UAF1 inhibitor links deubiquitination to DNA damage responses
Liang, Q., Dexheimer, T. S., Zhang, P., Rosenthal, A. S., Villamil, M. A., You, C., Zhang, Q., Chen, J., Ott, C. A., Sun, H., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1455 · Cited by 265
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Ling, X., Tu, J., Wang, J., Shajii, A., Kong, N., Feng, C., Zhang, Y., Yu, M., Xie, T., Bharwani, Z., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06400 · Cited by 263
Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting
Murakami, M., Cabral, H., Matsumoto, Y., Wu, S., Kano, M. R., Yamori, T., Nishiyama, N., & Kataoka, K. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001385 · Cited by 262
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Planells‐Cases, R., Lutter, D., Guyader, C., Gerhards, N. M., Ullrich, F., Elger, D. A., Kucukosmanoglu, A., Xu, G., Voss, F. K., Reincke, S. M., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201592409 · Cited by 256
Prakash, S., Malhotra, M., Shao, W., Tomaro-Duchesneau, C., & Abbasi, S. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.013 · Cited by 256
Mammalian metallothioneins: properties and functions
Babula, P., Masarik, M., Adam, V., Eckschlager, T., Stiborova, M., Trnkova, L., Skutkova, H., Provaznik, I., Hubalek, J., & Kizek, R. (2012) · Metallomics · doi:10.1039/c2mt20081c · Cited by 255
Review on gold nanoparticles and their applications
Das, M., Shim, K. H., An, S. S. A., & Yi, D. K. (2011) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-011-0109-y · Cited by 253
Kang, T.-H., Lindsey-Boltz, L. A., Reardon, J. T., & Sancar, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915085107 · Cited by 250
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
“This prompted the development of the less toxic analog carboplatin.(6) The primary mechanism of action of platinum compounds is adduct formation with nucleophilic groups in tumor cell DNA.”
BackgroundMurai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.009 · Cited by 172
Kopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2246 · Cited by 160
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139
Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer
Miow, Q. H., Tan, T. Z., Ye, J., Lau, J. A., Yokomizo, T., Thiery, J.-P., & Mori, S. (2015) · Oncogene · doi:10.1038/onc.2014.136 · Cited by 117
Deng, X., Li, Z., Li, G., Li, B., Jin, X., & Lyu, G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01607 · Cited by 114
Griffith, D., Morgan, M. P., & Marmion, C. J. (2009) · Chemical Communications · doi:10.1039/b916715c · Cited by 109
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Luo, R., Firat, E., Gaedicke, S., Guffart, E., Watanabe, T., & Niedermann, G. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1344 · Cited by 91
Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer
Aranda, F., Bloy, N., Pesquet, J., Petit, B., Chaba, K., Sauvat, A., Kepp, O., Khadra, N., Enot, D., Pfirschke, C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.234 · Cited by 89
McAdam, E., Brem, R., & Karran, P. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0053 · Cited by 86
“The toxicity of cisplatin is largely dependent on the induction of DNA damage and it is well established that NER significantly attenuates the therapeutic effectiveness of platinum drugs by removing potentially toxic platinum–DNA lesions (33).”
BackgroundWang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Fransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65
“Platinum-based drugs have for decades been used for effective treatment of many solid tumors, including ovarian cancer [25, 26].”
BackgroundWang, J., Nie, J.-J., Guo, P., Yan, Z., Yu, B., & Bu, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11013 · Cited by 66
Sail, V., Rizzo, A. A., Chatterjee, N., Dash, R. C., Ozen, Z., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01144 · Cited by 52
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
MiR-182-5p protects inner ear hair cells from cisplatin-induced apoptosis by inhibiting FOXO3a
Li, Y., Li, A., Wu, J., He, Y., Yu, H., Chai, R., & Li, H. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.246 · Cited by 46
Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer
Lin, X.-M., Li, S., Zhou, C., Li, R.-Z., Wang, H., Luo, W., Huang, Y.-S., Chen, L.-K., Cai, J.-L., Wang, T.-X., et al. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105610 · Cited by 43
Zhuang, Q., Zhou, T., He, C., Zhang, S., Qiu, Y., Luo, B., Zhao, R., Liu, H., Lin, Y., & Lin, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0341-z · Cited by 38
Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery
Matha, K., Lollo, G., Taurino, G., Respaud, R., Marigo, I., Shariati, M., Bussolati, O., Vermeulen, A., Remaut, K., & Benoit, J.-P. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.02.008 · Cited by 35
Perez, M., Lucena-Cacace, A., Marín-Gómez, L. M., Padillo-Ruiz, J., Robles-Frias, M. J., Saez, C., Garcia-Carbonero, R., & Carnero, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8880 · Cited by 34
MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer
Qian, X.-L., Zhou, F., Xu, S., Jiang, J., Chen, Z.-P., Wang, S.-K., Zuo, Y., & Ni, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638537 · Cited by 34
Parker, J. P., Nimir, H., Griffith, D. M., Duff, B., Chubb, A. J., Brennan, M. P., Morgan, M. P., Egan, D. A., & Marmion, C. J. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.03.011 · Cited by 32
Jin, X., Gong, L., Peng, Y., Li, L., & Liu, G. (2021) · Aging · doi:10.18632/aging.202137 · Cited by 24
“Cisplatin is widely used to treat a broad range of cancers [15, 16].”
BackgroundHuang, R., Sun, Y., Zhang, X.-Y., Sun, B.-W., Wang, Q.-C., & Zhu, J. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.05.013 · Cited by 21
Liskova, B., Zerzankova, L., Novakova, O., Kostrhunova, H., Travnicek, Z., & Brabec, V. (2012) · Chemical Research in Toxicology · doi:10.1021/tx200525n · Cited by 20
Biswas, R., Chung, P.-S., Moon, J. H., Lee, S.-H., & Ahn, J.-C. (2014) · Lasers in Medical Science · doi:10.1007/s10103-013-1452-9 · Cited by 19
Nanocarrier-based targeted pulmonary delivery: novel approaches for effective lung cancer treatment
Shah, M. R., Imran, M., & Ullah, S. (2019) · Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy · doi:10.1016/b978-0-12-816773-1.00006-7 · Cited by 5
(2013) · Digital Commons - East Tennessee State University (East Tennessee State University) · Cited by 3
Metadata
- Authors
- Kelland, L.
- Venue
- Nature Reviews Cancer
- Published
- 2007-07-12
- Volume
- 7
- Issue
- 8
- Pages
- 573-584
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2130177169
- Cited by
- 4,717
- References
- 85
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.